Fig. 1From: Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trialPatient disposition in the total efficacy and MRI/CRP-positive populations over 3 years. *Other reasons included lack of efficacy, pregnancy, investigator decision, patient moved, and protocol violation. OL Open label, OLE Open-label extensionBack to article page